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Abstract: Mutations in theEPM2A andEPM2B genes, encoding laforin and malin proteins respectively,
are responsible for Lafora disease, a fatal form of progressive myoclonus epilepsy with autosomal
recessive inheritance. Neuroimaging studies of patients with Lafora disease have shown different
degrees of brain atrophy, decreased glucose brain uptake and alterations on different brain metabolites
mainly in the frontal cortex, basal ganglia and cerebellum. Mice deficient for laforin and malin
present many features similar to those observed in patients, including cognitive, motor, histological
and epileptic hallmarks. We describe the neuroimaging features found in two mouse models
of Lafora disease. We found altered volumetric values in the cerebral cortex, hippocampus,
basal ganglia and cerebellum using magnetic resonance imaging (MRI). Positron emission tomography
(PET) of the cerebral cortex, hippocampus and cerebellum of Epm2a−/− mice revealed abnormal
glucose uptake, although no alterations in Epm2b−/− mice were observed. Magnetic resonance
spectroscopy (MRS) revealed significant changes in the concentration of several brain metabolites,
including N-acetylaspartate (NAA), in agreement with previously described findings in patients.
These data may provide new insights into disease mechanisms that may be of value for developing
new biomarkers for diagnosis, prevention and treatment of Lafora disease using animal models.
Keywords: Lafora disease; mouse models; volumetry; brain metabolites; MRI; FDG PET;
1H-HRMAS MRS
1. Introduction
Lafora disease (OMIM 254780, ORPHA 501) is a progressive myoclonic epilepsy that initiates
during adolescence, usually between 10 and 18 years of age, after an apparent normal development.
The first symptoms are epileptic seizures and/or cognitive alterations that cause school difficulties.
Cognitive decline rapidly produces intellectual and lexical problems. These symptoms progressively
worsen and patients develop severe dementia, ataxia, dysarthria, amaurosis and respiratory failure,
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which usually lead to death within 5 to 10 years of the onset of the disease [1,2]. There are no specific
therapies for the disease and patients are only treated with antiseizure medications, although seizures
rapidly develop resistance and myoclonus become constant.
The disease presents autosomal recessive inheritance with mutations found in two
genes, the Epilepsy Progressive Myoclonus type 2A (EPM2A) gene (OMIM 607566) encoding laforin,
a dual-specificity phosphatase [3–5] and the Epilepsy Progressive Myoclonus type 2B (EPM2B) gene
(OMIM 608072) encoding malin, an E3 ubiquitin ligase [6,7]. Lafora disease is an ultrarare disease with a
higher prevalence in regions with noted consanguinity. It is characterized by the presence of a distinctive
histological biomarker in the brain and other tissues: the abnormal inclusions of polyglucosans known
as Lafora bodies. Lafora bodies are composed of low-branched and hyperphosphorylated glycogen-like
molecules and can be identified with periodic-acid-Schiff (PAS)-staining [1,2,8–10].
Some studies of brain volumetry by magnetic resonance imaging (MRI) in patients with
Lafora disease showed normal values [11–13], especially early after diagnosis of the disease [14,15].
However, other studies have reported certain levels of brain atrophy in patients with Lafora disease
at different stages of the disease. Diffuse cortical [16,17], cerebellar [18], cerebral [19,20] or both,
cerebellar and cerebral [21–23] atrophy were observed in certain patients, mainly in more advanced
stages of the disease [15]. However, with 2-deoxy-2-[18F]fluoro-D-glucose (FDG)–positron emission
tomography (PET), a diffuse decrease in cortical [24] or cerebral [25] glucose metabolism has been
reported in several patients, especially in posterior areas, such as the cerebellum [26,27] and occipital
lobes [12]. A decrease in glucose metabolism has also been described in extensive areas of the brain in
a series of 8 patients, often involving multiple cortical and subcortical regions, such as the thalamus,
the temporal, frontal and parietal lobes [28]. Additionally, bilateral glucose hypometabolism in the
frontal, parietal and temporal lobes and in the auditory and sensorimotor cortex was reported in a case
of a young patient with Lafora disease [29].
In vivo 1H magnetic resonance spectroscopy (1H-MRS) studies in a series of 10 patients with Lafora
disease showed altered metabolite concentrations, mainly in the frontal and occipital cortex, cerebellum
and basal ganglia [11]. In particular, this study reported a decreased N-acetylaspartate/creatine
(NAA/Cr) ratio in the same regions, along with a decreased NAA/choline (NAA/Cho) ratio and an
increased Cho/Cr ratio in the frontal cortex. A study of 1[H] MRS in 5 patients [30] corroborated
the predominant involvement of the frontal cortex in Lafora disease, with a significant decrease in
NAA/Cr and NAA/Cho ratios and an increase of the Cho/Cr ratio in patients compared to controls.
Furthermore, a significant reduction in the NAA/Cho ratio in the cerebellum was found in a series of
12 patients with Lafora disease, along with an association between metabolite alterations and some
clinical parameters (myoclonus and ataxia) [31]. Recently, an in vivo study of 1[H] MRS study in
the thalamus of a Beagle dog showed a decrease in molar concentrations of glutamate + glutamine
(Glu+Gln), NAA and mIns + glycine (mIns+Gly) and higher concentrations of total Cho (tCho) and
phosphoethanolamine (PE) [23].
Null mouse models of Lafora disease have been generated by gene targeting deletion of either
Epm2a or Epm2b genes. Both mouse models, Epm2a−/−, lacking laforin expression [32] and Epm2b−/−,
null for malin expression [33], have symptoms similar to those observed in patients with the disease,
such as motor alterations, memory deficits, dyskinesia, epilepsy, neurodegenerative processes and
Lafora bodies, which have been extensively characterized in previous reports [32–35]. However, to our
knowledge, no data are available on the structural and functional alterations of Lafora disease mouse
brain caused by the absence of laforin or malin expression. In this article, we explore for the first
time the alterations observed in brain volume, glucose metabolism and brain metabolites through
in vivo MRI, FDG-PET and 1H-MRS ex vivo studies, in both Epm2a−/− and Epm2b−/− mouse models of
Lafora disease.
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2. Results
Manual MRI analysis of regions of interest (ROI) (Figure 1) showed a statistically significant
increased volume of the entire brain, cortex, cerebellum and hippocampus in the 6-month-old Epm2a−/−
mice compared with control mice (Figure 1A), while 16-month-old Epm2a−/− mice only showed a
significant increase in the volume of the cerebellum (Figure 1C). 6-month-old Epm2b−/− mice only
showed a significant increase in the entire brain volume (Figure 1B).
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Figure 1. Manual analysis of the volumetry differences between control and youngEpm2a−/− (A) (n = 12),
between control and young Epm2b−/− (B) (n = 12) and betwe n control and older Epm2a−/ (C) mice
(n = 20) in different ROIs measured on magnetic reson ce imaging (MRI). WB: whole brain; Cx: cortex;
Cb: cerebellum; Hippo: hippocampus; Vent: ventricles. * p < 0.05.
Voxel-based morphometry (VBM) analysis of the brain of Epm2a−/− and Epm2b−/− mice revealed
changes in the volume of grey matter (GM) and white matter (WM) in different regions (Figure 2).
Cerebrospinal fluid (CSF) analysis showed decreased volumes in the 3rd dorsal, 4th and lateral
ventricles of 6-month-old Epm2a−/− mice compared to controls (Figure 2A, CSF). After family-wise error
(FWE) correction, a significant decreased volume of the 4th ventricle of old Epm2a−/− mice (Figure 2C,
CSF) was found, with no statistically significant differences in younger mice. An increase in WM
and a decrease in GM volumes were observed in the basal ganglia of young Epm2a−/− and Epm2b−/−
mice (Figure 2A,B, GM, WM) and in the hippocampus of young Epm2b−/− and older Epm2a−/− mice
(Figure 2B,C, GM, WM and Supplementary Figure S1A). In young Epm2a−/− mice, the volume of WM
increased significantly after FWE correction in the hippocampus, while no statistically significant
changes were observed in the volume of GM (Figure 2A, GM, WM and Supplementary Figure S1A).
In the cerebellum, the increased volume of WM was present in Epm2a−/− and Epm2b−/−mice at 6 months
of age (Figure 2B, WM and Supplementary Figure S1B), while the volume of GM did not change in
either group. In the cerebral cortex, decreased GM and increased WM volumes were bserved i
the retrosplenial cortex of young Epm2a−/− mice (Figure 2A, GM, ; Rp-cx and Table 1) an i t e
sensorimotor c rte f old Epm2a−/− mice (Figure 2C, GM, WM; S -cx and Table 1). In old Epm2a−/−
mice, the GM volume increased significantly after FWE correction in the insular cortex/claustrum
(Figure 2C, GM; In-cx /Cl).
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Figure 2. Voxel-based morphometry (VBM) analysis of MRI in Lafora disease mice. VBM of CSF,
GM and WM showed a t-value (p < 0.05, k = 500 voxels) overlaid on the MRI reference, indicating
that the volume of the region increased (hot colors) or decreased (cold colors) in Epm2a−/− (A) and
Epm2b−/− (B) mice at 6 months of age and in Epm2a−/− mice at 16 months (C), compared to control
values. CSF: cerebrospinal fluid; GM: grey matter; WM: white matter. In-cx: insular cortex; Rp-cx:
retrosplenial cortex; SM-cx: sensorimotor cortex; D3rd, 4th and Lat Vent: dorsal 3rd, fourth and lateral
ventricles. Asterisks indicate significant clusters. Arrows indicate significant clusters that survived the
FWE correction.
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Table 1. Summary of volumetric and glucose uptake alterations in Lafora disease mouse models
observed by MRI and positron emission tomography (PET) analysis.
MRI PET
Manual (mm3) CSF GM WM SPM
6 months Epm2a
−/−
/Epm2b−/−
Epm2a−/−
/Epm2b−/−
Epm2a−/−
/Epm2b−/−
Epm2a−/−
/Epm2b−/−
Epm2a−/−
/Epm2b−/−
Cortex ↑/−
Sensorimotor cortex
Hippocampus ↑/− ∇/↓ ↑/∆ ↓/−
Basal ganglia ↓/−
Temporal cortex ↑/−
Retrosplenial cortex ∇/− ∆/− ↑/−
Ventricles ∇/−
Cerebellum ↑/− ∆/↑
Whole brain ↑/↑
16 months Epm2a−/− Epm2a−/− Epm2a−/− Epm2a−/− Epm2a−/−
Cortex
Sensorimotor cortex ↓ ∆ ↑
Hippocampus ↓ ↑
Basal ganglia
Insular-cx/claustrum ↑
Temporal cortex
Retrosplenial cortex
Ventricles ↓↓↓ 4th
Cerebellum ↑ ↑ ↑
Whole Brain
Empty spaces and (−) indicate no changes and arrows indicate p significance values: ↑ and ↓ p < 0.05. Arrows ∆
and ∇ indicate alterations with no statistically significant values after FWE correction.
Manual ROI analysis of FDG-PET revealed no differences in glucose uptake (Figure 3A,C,E and
Table 1). However, statistical parametric mapping (SPM) analysis showed a relative decrease in FDG
uptake in the hippocampus and an increase in the retrosplenial and temporal cortex of Epm2a−/− mice
at 6 months of age (Figure 3B and Table 1). Furthermore, older Epm2a−/− mice showed increased FDG
uptake in the cerebellum and sensorimotor cortex (Figure 3F and Table 1). No significant differences
were found in Epm2b−/− mice (Figure 3D and Table 1).
Ex vivo proton high resolution magic angle spinning (1H-HRMAS) analysis of Epm2a−/− and
Epm2b−/− mice at 6 months showed alterations of brain metabolites in different brain regions (Table 2
and Supplementary Figure S2). The metabolites with the most significant alterations in the entire
brain were gamma-aminobutyric acid (GABA), lactate (Lac), myo-Inositol (mIns), N-acetylaspartate
(NAA), phosphocreatine (PCr), glutamine + glutamate (Glu+Gln) and mIns + glycine (mIns+Gly)
normalized to total tCr (Cr+PCr) and the most affected regions were the cortex, hippocampus,
brainstem and cerebellum. Detailed description of the metabolite alterations is provided in Table 2
and in the Supplementary Data. The concentrations of acetate (Ace), alanine (Ala), aspartate (Asp),
glycerylphosphorylcholine (GPC), phosphocholine (PCho) and choline + glycerylphosphorylcholine
+ phosphocholine (Cho+GPC+PCho) normalized to tCr showed mild alterations in specific brain
regions of Lafora disease mouse models. NAA was markedly reduced in all brain regions of both mice,
with the exception of the cerebral cortex, while Lac levels increased in the frontal regions, mainly in
the prefrontal cortex, hippocampus and basal ganglia but also in the non-prefrontal cortex (cortex-)
(Table 2 and Supplementary Figure S2). The metabolite concentrations varied very similarly in the
Epm2a−/− and Epm2b−/− mice, although with less pronounced changes in the Epm2b−/− model (Table 2
and Supplementary Figure S2).
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Figure 3. 2-deoxy-2-[18F]fluoro-D-glucose (FDG) uptake in 6-month-old Epm2a−/− (A,B) and Epm2b−/−
(C,D) and 16-month old Epm2a−/− (E,F) mice compared to control mice. The bar graphs on the left
(A,C,E) show Standard Uptake Value mean (SUVmean) in the PET ROIs. No statistically significant
differences were found with ROI analysis. The right panel (B,D,F) shows the statistical parametric
mapping (SPM) t-values (p < 0.05, k = 25 voxels) overlaid on the reference MRI indicating an increase
(hot colors) or a decrease (cold colors) of FDG uptake. WB: whole brain; Cx: cortex; Cb: cerebellum;
Hippo: hippocampus; Vent: ventricles; Rp-cx: retrosplenial cortex; T-cx: temporal cortex; SM-cx:
sensorimotor cortex.
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Table 2. Regional brain metabolic changes observed ex vivo in the Proton High Resolution Magic Angle Spinning (1H-HRMAS) analysis of Epm2a-/- and Epm2b-/-
mice at 6 months of age.
[Ace]/[tCr] [Ala]/[tCr] [Asp]/[tCr] [GABA]/[tCr] [GPC]/[tCr] [Lac/tCr]
Epm2a−/−/Epm2b−/− Epm2a−/−/Epm2b−/− Epm2a−/−/Epm2b−/− Epm2a−/−/Epm2b−/− Epm2a−/−/Epm2b−/− Epm2a−/−/Epm2b−/−
PF-cortex −/↑ −/↑↑ ↑/↑↑
Cortex - ↑/− ↑/↑ ↑/↑
Hippocampus ↑↑/− ↑↑/↑ −/↑
Basal ganglia ↑↑/− ↑/↑
Thalamus ↑/−
Hypothalamus ↑/↑↑
Brainstem ↑↑/↑ ↓/↓ −/↓
Cerebellum ↑/− ↑/− ↑/−
[mIns]/[tCr] [NAA]/[tCr] [PCho]/[tCr] [Glu+Gln]/[tCr] [mIns+Gly]/[tCr] [Cho+GPC+PCho]/[tCr]
Epm2a−/−/Epm2b−/− Epm2a−/−/Epm2b−/− Epm2a−/−/Epm2b−/− Epm2a−/−/Epm2b−/− Epm2a−/−/Epm2b−/− Epm2a−/−/Epm2b−/−
PF-cortex ↑/↑ ↑/−
Cortex- ↑/− ↑↑/↑
Hippocampus ↓/↓ ↓↓/↓ ↑/−
Basal ganglia ↓/↓↓ ↓/↓ −/↓
Thalamus ↑↑/− ↓/↓↓ ↓/- ↑/−
Hypothalamus −/↓↓↓
Brainstem ↑/− ↓↓/↓↓↓ ↓/↓↓
Cerebellum ↓↓/↓↓↓ ↓/−
The metabolite concentrations were normalized to tCr [Cr+PCr], the [PCr]/[Cr] ratios were similar in all regions. Ace: acetate; Ala: alanine; Asp: aspartate; Cr: creatine; GABA:
gamma-aminobutyric acid; GPC: glycerylphosphorylcholine; Lac: lactate; mIns: myo-Inositol; NAA: N-acetylaspartate; PCho: phosphorylcholine; PCr: phosphocreatine; Gln+Glu:
glutamine + glutamate; mIns+Gly: myo-Inositol + glycine; Cho+GPC+PCho: choline + glycerolphosphorylcholine + phosphorylcholine. PF-cx: prefrontal cortex; Cortex-: cortex without
PF-cx. Empty spaces and (−) indicate no changes and arrows indicate p significance values: ↑ and ↓ p < 0.05; ↑↑ and ↓↓ p < 0.01 and ↓↓↓ p < 0.001.
Int. J. Mol. Sci. 2020, 21, 7771 8 of 15
3. Discussion
Patients with Lafora disease present with severe neurological deficiencies and brain abnormalities,
such as abnormal brain aggregates, neurodegenerative processes and epilepsy. Neuroimaging studies
in patients show different levels of brain atrophy, decreased brain glucose uptake and abnormalities in
brain metabolites, predominantly in the frontal cortex, basal ganglia and cerebellum. Mouse models
of Lafora disease present several symptoms similar to those observed in patients, although there are
no data available on structural and/or functional brain alterations derived from the lack of laforin or
malin expression. Detailed analysis of the brain imaging data in these models can help gain a deeper
insight into the causes of the disease.
In this work, ROI analysis of MRI studies showed hypertrophy of the cerebral cortex, whole-brain,
hippocampus and cerebellum in 6-month-old Epm2a−/− mice. Both Epm2a−/− mice at 6 and 16 months
of age showed an increased volume of cerebellum as assessed by the ROI analysis, while in this area
the SPM analysis showed an increased volume of WM volume without alterations in the volume of
GM. In the globus pallidus and striatum (basal ganglia) of young Epm2a−/− mice the volume of WM
also increased but the GM decreased. Alterations in the volumes of WM and GM were also observed
in other areas of the brain. Some of these areas showed reduced GM and increased WM volumes,
leading to non-significant differences in the total volume reported by ROI analysis, probably because
the changes in GM and WM compensated each other. These brain volumetric alterations in the volume
of WM and GM may be the basis for some of the neurological effects observed in Lafora disease mouse
models, such as cognitive deficits, motor and coordination impairments or hyperexcitability of the
neuronal network [32,33,35]. As mentioned above, MRI studies in patients showed the presence of
diffuse cerebral, cortical and/or cerebellar atrophy [15–22], findings opposite to those observed in
equivalent brain regions of Epm2a−/− mice. This discrepancy could be due to a possible inflammatory
mechanism that could arise in response to neuronal loss or other pathological events, leading to some
hypertrophy in our mouse models.
Most FDG-PET studies in patients with Lafora disease reported decreased glucose uptake,
either diffuse cortical [24] or in the entire brain [25] or localized to posterior areas, such as the occipital
cortex [12] and cerebellum [26,27]. Our SPM analysis showed an increased glucose uptake in the
cerebellum and the restrosplenial, temporal and sensorimotor cortices of young Epm2a−/− mice,
corresponding to the regions showing volumetric alterations with MRI. SPM analysis also showed a
reduction in glucose uptake in the hippocampus of Epm2a−/−mice at 6 months, which is also colocalized
with alterations in GM and WM volumes.
SPM analysis of PET studies demonstrated regional changes, such as increased glucose uptake
in the cerebellum and in the restrosplenial, temporal and sensorimotor cortices of young Epm2a−/−
mice. This increase in glucose metabolism could be related to the volumetric alterations observed
in these regions by MRI and may suggest the presence of hyperexcitability of neural networks,
although this correlation would require further investigation. SPM analysis of PET images also showed
reduced glucose uptake in the hippocampus of young Epm2a−/− mice. This glucose hypometabolism
could be related to the alterations in GM and WM volumes observed in the hippocampus and may
reflect the appearance of cellular damage due to the accumulation of Lafora bodies in this region as
disease progresses [32,36,37]. However, no statistically significant changes in glucose metabolism were
observed in the hippocampus of Epm2b−/− at 6 months or Epm2a−/−mice at 16 months of age, despite the
GM and WM volume abnormalities shown in this region. The Epm2b−/− mice did not show significant
differences in brain glucose uptake either. These data on the Epm2b−/− mouse model are consistent
with previous reports showing that mutations in the EPM2B gene in patients with Lafora disease
have a slightly milder clinical course [38]. The laforin gene is predominantly expressed in the cerebral
cortex, hippocampus, basal ganglia and cerebellum and its expression increases until adulthood
in other regions of the mouse brain [36]. In our work, abnormalities in the volumetric values and
glucose metabolism were observed predominantly in the cerebral cortex, hippocampus and cerebellum,
correlating with regions of higher expression of laforin and accumulation of Lafora bodies [32,33,35,39].
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When comparing our results with patient data, we observe certain inconsistent findings, since the same
regions that presented hypometabolism in the patients instead showed hypermetabolism in our models.
These results could be explained by a possible inflammatory mechanism in our mouse models that
leads to some hypermetabolism in the same regions where patients show atrophy and hypometabolism.
Ex vivo 1H-HRMAS analysis in Epm2a−/− and Epm2b−/− mouse models revealed abnormal
metabolite patterns in all areas analyzed. Metabolite concentrations varied similarly in the Epm2a−/−
and Epm2b−/− mice, although less pronounced in the Epm2b−/− mouse model, consistent with the milder
phenotype of this mutant. NAA is a marker of neuronal density and viability and its levels decreases
with neuronal dysfunction and destruction [40]. mIns is a glial marker that usually increases when
astrocyte activation and proliferation occurs. Total Cr is relatively constant and is frequently used as a
reference metabolite for in vivo MRS analysis. Summarizing the results of both models, the levels of
GABA, Ace, Ala, Lac andmIns increased in different regions, while NAA was significantly reduced in all
brain regions in both models of Lafora disease, with the exception of the cerebral cortex. This contrasts
with the observed reduction of this metabolite in the frontal cortex of patients [11]. Decreased levels of
NAA in the hippocampus may reflect the existence of neurodegenerative processes, in agreement with
previous reports showing a reduced number of neurons in this area [32,33]. Although the levels of NAA
did not show changes in the cerebral cortex, many other metabolites were altered in this region, with the
levels of Ala, GABA, Lac, mIns andmIns+Gly more increased. Elevated lactate levels were also observed
in the prefrontal cortex, hippocampus and basal ganglia of both models, suggesting abnormal energetic
metabolism and/or hyperexcitability. An increased in the lactate level is observed during hypoxia or in
general conditions of energy deficiency. However, the Glu+Gln/tCr ratio decreased in hippocampus,
basal ganglia, brainstem and cerebellum, with no changes in frontal cortex, contrary to what occurs in
idiopathic generalized epilepsy, where an increase in the glutamate plus glutamine ratio was observed
in frontal lobes by in vivo MRS analysis [41]. Elevated levels of lactate and reduced glutamate are
observed during situations of decreased global glucose consumption, which could be occurring in
the hippocampus, as observed with FDG-PET. Overall, the ex vivo 1H-HRMAS analysis of Epm2a−/−
and Epm2b−/− mice showed alterations in regions that coincide with those in which neuropathological
studies have demonstrated the presence of Lafora bodies, with a predominant location in cortex,
hippocampus, basal ganglia, thalamus, brainstem and cerebellum [32,33,39]. This correlation may
indicate that Lafora bodies can produce neurotoxic consequences and lead to neuronal loss and
astrocytosis, as has been widely reported [32–34,37,39,42].
Although the Epm2a−/− and Epm2b−/− mouse models show similar phenotypic characteristics [39],
the Epm2b−/− mice occasionally exhibits some milder neurological abnormalities, such as reduced
hypersensitivity to PTZ, less motor coordination impairments and, as we showed above,
minor deficiencies in several neuroimaging variables. Furthermore, the analysis of glucose metabolism
in the heart, as observed with FDG-PET, shows increased glucose uptake in Epm2a−/− mice [43] and no
changes in the Epm2b−/− mouse model [44]. Both models present in older ages milder spontaneous
movements and motor coordination alterations similar to those found in younger mice, while the
memory decline, the hindlimb clasping and the number of LBs increase with age [39]. The mismatch
between age and severity of these neurological anomalies requires further studies, as no data are
available from aged patients with the disease.
To the best of our knowledge, this is the first study to evaluate structural and functional
brain alterations in mouse models of Lafora disease. In conclusion, our in vivo and ex vivo brain
imaging findings reveal that Epm2a−/− mice present hypertrophy, abnormal glucose uptake and
altered brain metabolites predominantly in the cerebral cortex, basal ganglia, hippocampus and
cerebellum, correlating with regions of higher expression of laforin and accumulation of Lafora bodies.
Epm2b−/− mice show brain metabolic changes comparable to those present in Epm2a−/− mice and in
some brain regions of patients with Lafora disease, although Epm2b−/− mice shows milder volumetric
alterations and normal glucose metabolism. Further neuroimaging studies may define new biomarkers
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and shed light into the basic mechanisms of the disease and may lead to new avenues for the diagnosis,
prevention and treatment of Lafora disease.
4. Materials and Methods
4.1. Animals
Epm2a−/− and Epm2b−/− knock-out mice were generated as previously described [32,33]. We used
12 Epm2a−/−, 12 Epm2b−/− and 12 wild type (wt) mice at 6 months of age to undergo MRI, PET and MRS
studies. In addition, 20 Epm2a−/− and 11 wt mice were used for MRI and PET studies at 16 months
of age.
Mice were housed in standard size cages, subjected to a 12h light/dark cycle at constant temperature
(23 ◦C) and with ad libitum access to food (standard diet, Safe Scientific Animal Food & Engineering,
Augy, France) and water. All experiments were carried out using and sacrificing the minimum number
of animals and minimizing their suffering.
The experiments were conducted in accordance with the “Principles of laboratory animal care”
(NIH publication No. 86-23, revised 1985), as well as with the European Communities Council Directive
(2010/63/EU) and the Ethical Review Board of the IIS-Fundación Jiménez Díaz.
4.2. In Vivo Imaging
For brain MRI and FDG-PET studies, animals were maintained under sevoflurane anesthesia
(5% induction and 2% maintenance, in 100% O2). MRI was obtained with a 7 Tesla BioSpec 70/20 scanner
(Bruker, Ettlingen, Germany). A T2-weighted axial RARE sequence was acquired with TR = 4600 ms,
TE = 65 ms, 10 averages, rare factor = 8 and slice thickness of 0.5 mm (30 slices). The size of the matrix
was 192 × 192 pixels with a field of view (FOV) of 20 × 20 mm2. Brain FDG-PET studies were carried
out with a SuperArgus small animal PET-CT scanner (SEDECAL, Madrid, Spain). PET images were
acquired 45 min after intravenous administration of 17−18 MBq FDG. Data was collected over 30 min
and reconstructed using OSEM-2D with 16 subsets and 2 iterations. After PET, computed tomography
(CT) images were acquired using an X-ray beam current of 240 µA and a tube voltage of 40 kVp and
reconstructed with an FDK algorithm [45].
4.3. Brain Image Analysis
For manual analysis, Multimodality Workstation software (MMWKS) [46] was used to define
ROIs of the entire brain, cortex, hippocampus, cerebellum and ventricles by a single MRI expert and
then applied to the co-registered PET images to get their mean standard uptake value (SUVmean).
Values are given as mean ± standard error of mean (SEM). The differences between the groups were
analyzed using the Student’s t-test. The thresholds of statistical significance were * p < 0.05; ** p < 0.01;
*** p < 0.001.
Voxel-wise analysis was obtained using the SPM12 package (http://www.fil.ion.ucl.ac.uk/
spm/software/spm12) (UCL, London, United Kingdom) using VBM for MRI and SPM for PET.
Regarding VBM analysis, a template image was generated using all the original MRI images of the
mouse brain, generating WM, GM and CSF tissue masks. Group differences were evaluated using
a Student’s t-test design and establishing a significance threshold of p < 0.05 in clusters of at least
500 voxels. To control for multiple comparisons, a FWE correction was performed. The clusters that
maintained a significant difference are highlighted with arrows (p < 0.001; p < 0.05) in the figures.
For the SPM analysis, the CT images of each animal were registered on the MRI and the spatial
transformations obtained were applied to the PET images. PET images were then normalized to global
mean brain activity and compared between groups with a Student´s t-test design with a significance
level of p < 0.05 in clusters of at least 25 pixels.
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4.4. Ex Vivo 1H-HRMAS MRS Analysis
Animals were sacrificed after in vivo brain imaging. A Muromachi Microwave Applicator,
Model TMW-6402C (Toshiba, Tokyo, Japan), was used to sacrifice unanesthetized mice by exposing the
head to the microwave beam, with a power setting of 5.5 kW and an exposure time 1.6 s. After sacrifice,
brains were removed and regions of interest were dissected: prefrontal cortex (PF-cx), rest of
cortex without prefrontal cortex (Cx−), hippocampus (Hippo), hypothalamus (Hyp), thalamus (Thal),
brainstem (BS), basal ganglia (BG) and cerebellum (Cb) and frozen in liquid nitrogen. Samples were
stored at −80 ◦C until use.
The ex vivo 1H spectra were obtained with an AVANCE 11.7 Tesla spectrometer
(Bruker, Ettlingen, Germany) equipped with a 4 mm triple channel 1H/13C/31P HR-MAS, using a 1H
resonance probe with a sample spin rate of 4000 Hz. Samples (10 mg) were introduced into 50 µL
zirconia rotor (4 mm outer diameter, OD) with 50 µL D2O and centrifugated at 5.000 Hz at 4 ◦C to
avoid tissue degradation processes. Two types of monodimensional proton spectra were acquire
using a water-suppressed spin-echo Carr-Purcell-Meiboom-Gill (CPMG) sequence with TE = 36 ms,
TR = 144 ms and 128 scans. Data were collected into 64 k data points using a spectral width of 10 kHz
(20 ppm) and a 2 s water relaxation/presaturation delay. All spectra were analyzed using the LC Model
software (Oakville, ON L6J, Canada) [47] and a prior knowledge-based spectral fit algorithm.
Only the peak concentrations obtained with a standard deviation lower than 20% were evaluated.
Metabolites evaluated are detailed in the Legend of Figure S2 in Supplementary Data. Metabolite values
are reported normalized to total creatine concentration (tCs: creatine + phosphocreatine, Cr+PCr).
1H-HRMAS values are given as mean ± standard error of mean (SEM). The differences between
the groups were analyzed using one-way Anova (Graph-PadPrism 6.0, San Diego, CA, USA),
using statistical significance thresholds of * p < 0.05; ** p < 0.01; *** p < 0.001.
5. Conclusions
Epm2a−/− and Epm2b−/− mouse models of Lafora disease present alterations in the volume of the
hippocampus and cerebellum.
Epm2a−/− mice also show volume abnormalities in several areas of the cerebral cortex.
In the Epm2a-/- mouse model, decreased glucose uptake in the hippocampus and increased glucose
uptake in the cerebellum and certain cortical areas were observed.
MRS reveals changes in the concentration of brain metabolites predominantly in the cortex,
basal ganglia, hippocampus, thalamus, brainstem and cerebellum of both models.
Structural and functional abnormalities in Lafora disease mouse models are predominantly
observed in areas of the brain previously described in patients with Lafora disease.
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/20/7771/s1,
Figure S1: VBM analysis of MRI in hippocampus and cerebellum of Lafora disease mice; Figure S2: Brain metabolite
alterations observed ex-vivo by 1H-HRMAS analysis in young Epm2a−/− and Epm2b−/− mice)
Author Contributions: D.F.B.: Investigation, Formal analysis, Resources. L.C.: Methodology, Formal analysis,
Writing–Review. G.S.E.: Conceptualization, Investigation, Resources. D.C.: Methodology, Formal analysis,
Review. M.B.P.: Software, Formal analysis. M.D.: Supervision, Writing–Review. J.M.S.: Funding acquisition,
Writing–Review. M.P.S.: Funding acquisition, Writing–Review & Editing. All authors have read and agreed to the
published version of the manuscript.
Funding: This work has been supported by grants from the National Institute of Neurological Disorders and
Stroke of the National Institutes of Health (P01NS097197), the Spanish Ministry of Economy (SAF2014-59594-R
awarded to José M. Serratosa and Rti2018-095784b-100SAF awarded to José M. Serratosa and Marina P. Sánchez)
and the Community of Madrid (S2017/BMD-3867 RENIM-CM) and cofunded with European structural and
investment funds. The CNIC is supported by the ISCIII, the Ministerio de Ciencia e Innovación and the Pro CNIC
Foundation and is a Severo Ochoa Center of Excellence (SEV-2015-0505). GSE was supported by a fellowship from
the Conchita Rábago Foundation.
Acknowledgments: We thank Alexandra de Francisco, Yolanda Sierra and María de la Jara Felipe for their
excellent work with animal preparation and imaging protocols and the Animal Facilities Service of the Fundación
Instituto de Investigación Sanitaria-Fundación Jiménez Díaz. We also thank Teresa Navarro for her excellent
Int. J. Mol. Sci. 2020, 21, 7771 12 of 15
work and help with 1H-HRMAS and ROI MRI and Sebastian Cerdán for helpful comments and critical reading of
the manuscript.
Conflicts of Interest: The authors declare no conflict of interest. None of the authors has any conflict of interest to
disclose. We confirm that we have read the Journal’s position on issues involved in ethical publication and state
that this report is consistent with those guidelines.
Abbreviations
1H-HRMAS Proton High Resolution Magic Angle Spinning
Ace Acetate
Ala Alanine
Asp Aspartate
BG Basal Ganglia
BS Brainstem
Cb Cerebellum
Cho+GPC+PCho Choline + Glycerylphosphorylcholine + Phosphocholine
Cx- Rest of the cortex without prefrontal cortex
CSF Cerebrospinal Fluid
CT Computed Tomography
EPM2A Epilepsy Progressive Myoclonus type 2A
EPM2B Epilepsy Progressive Myoclonus type 2B
FDG 2-[18F] fluoro-D-glucose
FEW Family-Wise-Error
GABA Gamma-aminobutyric acid
Glu+Gln Glutamate + Glutamine
GM Gray Matter
GPC Glycerylphosphorylcholine
Hippo Hippocampus
1H-MRS 1H magnetic resonance spectroscopy
Hyp Hypothalamus
Lac Lactate
mIns myo-Inositol
mIns+Gly mIns + glycine
MRI Magnetic Resonance Imaging
NAA N-acetylaspartate
NAA/Cho NAA/choline
NAA/Cr NAA /creatine
NAA/mIns NAA/myo-Inositol
PAS Periodic-acid-Schiff
PCho Phosphocholine
PCr Phosphocreatine
PE Phosphoethanolamine
PET Positron-Emission Tomography
PF-cx Prefrontal cortex
ROI Regions Of Interest
SD Standard Deviation
SEP Somatosensory Evoked Potentials
SPM Statistical Parametric Mapping
SUVmean Standard Uptake Value mean
tCho total Cho
tCr total Creatine (Cr+PCr)
Thal Thalamus
VBM Voxel-Based Morphometry
WM White Matter
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